2015 - RAS Dialogue Blog
-
Mutations in Human Cancers Through the Lens of KRAS
Exome sequences from The Cancer Genome Atlas were analyzed for the types of missense mutations in KRAS that were associated with missense mutations in other commonly mutated genes.
-
Nanotechnology for Treating Cancer: Pitfalls and Bridges on the Path to Nanomedicines
Despite their promise, only a few nano-formulated drugs are used in humans. The NCI Nanotechnology Characterization Lab helps companies and academic investigators maximize their chance of successful clinical use.
-
Ras: Do We Know Its Structure Well Enough?
Carla Mattos discusses how subtle changes in distant parts of RAS molecules may influence the conversion of GTP to GDP that is fundamental to RAS signaling.
-
Enzymology of GTP-competitive RAS inhibitors
RAS molecules have affinities for GTP and GDP that are in the picomolar range. Ken Westover argues that covalent inhibitors of RAS are logical drug candidates.
-
RAS Insight
David Heimbrook, now CEO of the Frederick National Laboratory for Cancer Research, played a major role in a large pharma as it tried to develop an anti-RAS drug. Lessons from that failure inform the RAS Initiative today.